

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2062 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2062 Injection (a double-stranded small interfering RNA (siRNA) drug) (the “**Product**”), a Class 1 new chemical drug independently developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a siRNA drug which delivers through N-acetylgalactosamine (GalNAc) conjugation. It can target and inhibit angiotensinogen (AGT) for the treatment of hypertension. The Product can achieve a more sustained gene silencing effect through sequence optimization and chemical modification strategy, with the potential to become a stable antihypertensive drug administered once every six months. Preclinical studies demonstrated that the Product had a significantly longer duration of pharmacological activity than other siRNA products of the same type. It is expected to have differential advantages of long-lasting efficacy, good safety profile and improved medication adherence, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 23 December 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.